Overview

Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo

Status:
Unknown status
Trial end date:
2016-01-01
Target enrollment:
0
Participant gender:
All
Summary
Vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin. It has a major psychosocial impact on affected patients. There are many treatment modalities available for vitiligo, however, none of them cure the disease. Topical corticosteroids (CS) are the most effective monotherapy for localized vitiligo. Treatment with intralesional corticosteroids (ILCS) is commonly used in many dermatologic conditions. However, there are only a few studies published on the use of ILCS in vitiligo. This is a prospective double-blind randomized clinical trial to assess efficacy and safety of ILCS in the treatment of vitiligo. Four treatment sessions will be done over 4 to 6 months. The investigators will compare intralesional triamcinolone acetonide (active treatment) to normal saline (placebo).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of British Columbia
Treatments:
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Criteria
Inclusion Criteria:

- Age > 18 years.

- Localized or generalized vitiligo that involves a non mucosal or acral site.

- Patients should have a patch of at least 5 cm in the smallest diameter that shows no
more than 10% repigmentation as assessed visually

Exclusion Criteria:

- Patients who received treatment for vitiligo within the past 4 weeks.

- Hypersensitivity to TA or vehicle.

- Pregnancy or breast-feeding.